Baz Mariana, Paskel Myeisha, Matsuoka Yumiko, Zengel James R, Cheng Xing, Treanor John J, Jin Hong, Subbarao Kanta
Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, Maryland, USA.
MedImmune LLC, Mountain View, California, USA.
J Virol. 2015 Jul;89(13):6907-17. doi: 10.1128/JVI.00280-15. Epub 2015 Apr 22.
H3N8 influenza viruses are a commonly found subtype in wild birds, usually causing mild or no disease in infected birds. However, they have crossed the species barrier and have been associated with outbreaks in dogs, pigs, donkeys, and seals and therefore pose a threat to humans. A live attenuated, cold-adapted (ca) H3N8 vaccine virus was generated by reverse genetics using the wild-type (wt) hemagglutinin (HA) and neuraminidase (NA) genes from the A/blue-winged teal/Texas/Sg-00079/2007 (H3N8) (tl/TX/079/07) wt virus and the six internal protein gene segments from the ca influenza A virus vaccine donor strain, A/Ann Arbor/6/60 ca (H2N2), the backbone of the licensed seasonal live attenuated influenza vaccine. One dose of the tl/TX/079/07 ca vaccine induced a robust neutralizing antibody response against the homologous (tl/TX/079/07) and two heterologous influenza viruses, including the recently emerged A/harbor seal/New Hampshire/179629/2011 (H3N8) and A/northern pintail/Alaska/44228-129/2006 (H3N8) viruses, and conferred robust protection against the homologous and heterologous influenza viruses. We also analyzed human sera against the tl/TX/079/07 H3N8 avian influenza virus and observed low but detectable antibody reactivity in elderly subjects, suggesting that older H3N2 influenza viruses confer some cross-reactive antibody. The latter observation was confirmed in a ferret study. The safety, immunogenicity, and efficacy of the tl/TX/079/07 ca vaccine in mice and ferrets support further evaluation of this vaccine in humans for use in the event of transmission of an H3N8 avian influenza virus to humans. The human and ferret serology data suggest that a single dose of the vaccine may be sufficient in older subjects.
Although natural infection of humans with an avian H3N8 influenza virus has not yet been reported, this influenza virus subtype has already crossed the species barrier and productively infected mammals. Pandemic preparedness is an important public health priority. Therefore, we generated a live attenuated avian H3N8 vaccine candidate and demonstrated that a single dose of the vaccine was highly immunogenic and protected mice and ferrets against homologous and heterologous H3N8 avian viruses.
H3N8流感病毒是在野生鸟类中常见的一种亚型,通常在受感染鸟类中引起轻微疾病或不致病。然而,它们已经跨越物种屏障,并与狗、猪、驴和海豹的疫情有关,因此对人类构成威胁。通过反向遗传学,利用来自A/蓝翅鸭/德克萨斯/Sg - 00079/2007(H3N8)(tl/TX/079/07)野生型(wt)病毒的血凝素(HA)和神经氨酸酶(NA)基因以及来自冷适应(ca)甲型流感病毒疫苗供体株A/安阿伯/6/60 ca(H2N2)(已获许可的季节性减毒活流感疫苗的主干)的六个内部蛋白基因片段,构建了一种减毒活、冷适应(ca)H3N8疫苗病毒。一剂tl/TX/079/07 ca疫苗诱导了针对同源(tl/TX/079/07)和两种异源流感病毒的强大中和抗体反应,这两种异源流感病毒包括最近出现的A/港海豹/新罕布什尔/179629/2011(H3N8)和A/针尾鸭/阿拉斯加/44228 - 129/2006(H3N8)病毒,并对同源和异源流感病毒提供了强大的保护。我们还分析了针对tl/TX/079/07 H3N8禽流感病毒的人血清,在老年受试者中观察到低但可检测到的抗体反应性,这表明较旧的H3N2流感病毒赋予了一些交叉反应性抗体。在雪貂研究中证实了后一观察结果。tl/TX/079/07 ca疫苗在小鼠和雪貂中的安全性、免疫原性和有效性支持在人类中进一步评估该疫苗,以备H3N8禽流感病毒传播给人类时使用。人和雪貂的血清学数据表明,单剂量疫苗对老年受试者可能就足够了。
虽然尚未报告人类自然感染禽H3N8流感病毒,但这种流感病毒亚型已经跨越物种屏障并有效地感染了哺乳动物。大流行防范是一项重要的公共卫生优先事项。因此,我们构建了一种减毒活禽H3N8疫苗候选物,并证明单剂量疫苗具有高度免疫原性,可保护小鼠和雪貂免受同源和异源H3N8禽病毒感染。